Stem Cell Clinic

MacroGenics to Participate in Upcoming Investor Conferences

By Global News Feed

ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:

Continued here:
MacroGenics to Participate in Upcoming Investor Conferences

Supernus Provides Regulatory Updates for SPN-812 and SPN-830

By Global News Feed

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease (PD).

Read more from the original source:
Supernus Provides Regulatory Updates for SPN-812 and SPN-830

Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

By Global News Feed

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).

Excerpt from:
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

Minaris invests to triple capacity in Europe – Bioprocess Insider – BioProcess Insider

By Somatic Stem Cells

The cell and gene therapy CDMO will build additional facilities at its German and Japanese locations.

The contract development and manufacturing organization (CDMO) specializing in cell and gene therapies announced two separate investments of $40.7 million (34.2 million) into its Ottobrunn, Germany, site, and $23.8 million for its Yokohama, Japan, site.

Both regions now come under the umbrella of Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, after a rebrand in September to unify the name of its three businesses located in North America (previously, Hitachi Chemical Advanced Therapeutics Solutions (HCATS)), Europe (apceth Biopharma), and Japan (Hitachi Chemical).

Image: iStock/oatawa

The Japanese company acquired apceth last year for $86 million and will now add a 6,650-square-meter facility to the German site. The space will include additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space.

Once operational in 2023, the facility will more than triple the current clean room capacity.

A spokesperson for Minaris explained that the facility will feature a modular design, which allows the company to combine two smaller units into one large ball room and to shift from a grade B to grade C to grade B environment according to our clients needs.

The European site became one of the first CDMOs to manufacture a commercial gene therapy, after agreeing a deal with bluebird bio to manufacture its Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) product last year.

While the companys Japanese site will also receive an additional facility, which will cover 4,000-square-meters and is scheduled to start operations in October 2022.

The space will be used specifically for the commercial manufacture of regenerative medicine, particularly cancer immunotherapies and somatic stem cells, doubling the sites existing capacity.

Minaris global presence for a cell and gene specialist is unusual for an industry often concentrated in the US. However, the spokesperson for Minaris outlined that a global position confers an advantage to our clients that are seeking a global manufacturer to produce their product in different regions for example, clients with autologous cell products that need a manufacturing site close to the patients.

Additionally, We have regulatory expertise in Europe, Japan and the US and can leverage the expertise of one region to another, the spokesperson added.

Read the rest here:
Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider

Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 – PRnews Leader

By Somatic Stem Cells

Prophecy Market Insights added a recent Cell Therapy Manufacturing market report with Revenue, Key Developments, Top Countries Data, SWOT Analysis, COVID-19 impact, Growth and Outlook To 2029 to its research database. The report includes analysis of different factors that drives the market growth. It includes drivers, restrains, opportunities, and trends for the market. Further, the report provides the scope of different segments and applications which can promote the market over the forecast period. The in-depth information is based on historic milestones and current trends.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The report offers detailed information of the growth and other aspects of the Cell Therapy Manufacturing market in different regions, including North America, Europe, Asia pacific, and Middle East & Africa. Key regions covered in the report are the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc.

Australia, New Zealand, Rest of Asia-Pacific

Further, the report also provides the economic, environmental, social, technological, and political status of each region. This section also analyses region-wise revenue and volume for the forecasted period 2019-2029.

Cell Therapy Manufacturing Market by Top Manufacturers:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Competitive landscape section of the Cell Therapy Manufacturing report includes top ten manufacturers along with heat map analysis. The comprehensive report provides a significant microscopic look offering product portfolio, key highlights, financial overview, and business strategies.

Key Takeaways of the market report:

Key Topics Covered:

Important Questions Answered in Cell Therapy Manufacturing Market Report:

Segmentation Overview:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/21

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

Report Scope

Europe

Asia Pacific

Latin America

Middle East & Africa

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the original post:
Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader

Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 – TechnoWeekly

By Embryonic Stem Cells

Human Embryonic Stem Cells (HESC) Market Size And Forecast

A comprehensive overview of the Human Embryonic Stem Cells (HESC) Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Human Embryonic Stem Cells (HESC) Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Human Embryonic Stem Cells (HESC) Market. Furthermore, the Human Embryonic Stem Cells (HESC) Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Human Embryonic Stem Cells (HESC) Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Human Embryonic Stem Cells (HESC) Market growth opportunities over the forecast period.

Impact of Covid-19 :

During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Human Embryonic Stem Cells (HESC) Market which helps in making strategic decisions over the forecast period.

Competitive Landscape:

The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Human Embryonic Stem Cells (HESC) Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.

Following key players have been profiled with the help of proven research methodologies:

The Human Embryonic Stem Cells (HESC) Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Human Embryonic Stem Cells (HESC) Market Segmentation:

Human Embryonic Stem Cells (HESC) Market Segment by Type:

Human Embryonic Stem Cells (HESC) Market Segment by Application:

Human Embryonic Stem Cells (HESC) Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Human Embryonic Stem Cells (HESC) Market? Which factors are influencing the Human Embryonic Stem Cells (HESC) Market over the forecast period? What are the global challenges, threats and risks in the Human Embryonic Stem Cells (HESC) Market? Which factors are propelling and restraining the Human Embryonic Stem Cells (HESC) Market? What are the demanding global regions of the Human Embryonic Stem Cells (HESC) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read more:
Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly

Voters asked to approve $5.5 billion for stem cell research – Lebanon Express

By Embryonic Stem Cells

We built something good, but I think the field has expanded and there's plenty of money going into research in California now, said Jeff Sheehy, who sits on the governing board of the California Institute for Regenerative Medicine but says the state can't afford to borrow more bond money to support it.

When voters approved the initial $3 billion in 2004, President George W. Bush's administration had banned the use of federal funds for research using newly created human embryonic stem cell lines. The Obama administration lifted that ban in 2009.

Since then, opponents say, the National Institutes of Health has provided $1.5 billion a year in stem cell research money, while private investment in companies doing stem cell research has flowed in.

Supporters say that federal money could stop at any time, noting more than 90 members of Congress recently signed a letter demanding the Trump administration put an end to funding stem cell research.

More than a third of the initial $3 billion was spent to create stem cell research facilities at Stanford, the University of California, Berkeley, and other prestigious California institutions. Much of the rest has gone toward research.

With only about $30 million left, the California Institute for Regenerative Medicine has reduced its staff and stopped funding new studies.

If the proposition keeps its lead and passes, at least $1.5 billion would be earmarked for developing treatments for Alzheimer's, Parkinson's and other brain-related diseases. Some funds would be used to train California university and college students, and no more 7.5% could be used for administrative costs.

Go here to read the rest:
Voters asked to approve $5.5 billion for stem cell research - Lebanon Express

→←